Status:
TERMINATED
Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder
Lead Sponsor:
Anna Rose Childress, Ph.D.
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine Use Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a phase II, randomized, single-blind, placebo-controlled study to examine whether cariprazine (1.5 or 3 mg/d) 1) alters brain and/or behavioral responses to probes of reward and inhibition and...
Eligibility Criteria
Inclusion
- Inclusion Criteria (limited):
- An informed consent voluntarily signed and dated by the subject.
- Physically healthy males and females with cocaine use disorder.
- Ability to read at or above eighth grade level and speak, understand, and write in English.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Available for an inpatient stay, when applicable.
- Exclusion Criteria (limited):
- Certain psychological disorders that could put subjects at risk during participation in the study.
- Certain lifetime or current medical disorders or conditions that could put subjects at risk during participation in the study.
- Medical contraindications for MRI, when applicable.
- Has received medication that could interact adversely with cariprazine within the time of administration of study agent based on the study physician's guidance.
Exclusion
Key Trial Info
Start Date :
April 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 4 2020
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03430544
Start Date
April 4 2018
End Date
September 4 2020
Last Update
September 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104